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Background:  National  vaccine  adoption  decisions  may  be better  understood  by  linking  multiple  data
sources.  When  examining  countries’  decisions  to adopt  the  hepatitis  A vaccine,  applying  multiple  research
methods  can  facilitate  assessments  of  gaps  between  evidence  and policy.  We  conducted  a literature
review  on  hepatitis  A  and  stakeholder  interviews  about  decisions  to adopt  the  vaccine  in six  countries
(Chile,  India,  South  Korea,  Mexico,  Russia,  and Taiwan).
Methods:  A  systematic  literature  review  was  conducted  across  ﬁve  literature  databases.  The  review  identi-
ﬁed and abstracted  340  articles,  supplemented  by  internet  search.  In addition,  we interviewed  62 experts
and  opinion  leaders  on  hepatitis  A and/or  vaccines.  Data  from  the two  sources  were  analyzed  to identify
gaps  around  epidemiologic  data,  economic  data,  and  barriers/facilitators  of hepatitis  A  vaccine  adoption.
Results:  Epidemiologic  data  gaps  were  found  in  Chile  and  Russia,  where  stakeholders  believed data  to  be
more solid  than  the  literature  documented.  Economic  data  on  hepatitis  A was  found  to  be weak  across  all
countries  despite  stakeholders’  agreement  on its  importance.  Barriers  and  facilitators  of vaccine  adoption
such as political  will, prioritization  among  vaccines,  and  global  or local  recommendations  were  discussed
more  by  stakeholders  than  the  literature.  Stakeholders  in  India  and  Mexico  were  not  concerned  with  the
lack of  data,  despite  growing  recognition  in  the literature  of  the  epidemiological  transition  and  threat  of
outbreaks.
Conclusions:  Triangulation  of results  from  two  methods  captured  a richer  story  behind  vaccine  adoption
decisions  for  hepatitis  A.  The  discrepancy  between  policymakers’  beliefs  and  existing  data  suggest  a
decline  in  priority  of  hepatitis  A or  weak  investment  in  data  collection.  Filling  the conﬁrmed  data  gaps  in
seroprevalence  or economic  data  is  important  to help  guide  policy  decisions.  Greater communication  of
the risk  of  hepatitis  A and  the beneﬁts  of  the vaccine  may  help  countries  undergoing  the  epidemiologic
transition.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. IntroductionUsing one research methodology is often not enough to tell a
ull story especially for national vaccine adoption decisions, which
ften require diverse viewpoints to understand the complete
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picture. Applying multiple research methods and triangulating
results may  capture elements of the story that might be over-
looked by one method or the other. In this paper, we  apply two
research methods in examining decisions to adopt a new vaccine
where notable gaps may  exist between evidence and policy. These
gaps may  be particularly important for considerations to add the
hepatitis A vaccine into national immunization schedules given
the unique characteristics of the epidemiological transition that
moves countries from high to low endemicity of hepatitis A.
Hepatitis A is an acute liver disease caused by the hepatitis A
virus, which is preventable by available safe and highly efﬁcacious
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
Background characteristics of six countries.
Key indicators Chile India South Korea Mexico Russia Taiwan
Health Endemicity of Hep A, WHO  Classiﬁcationb Intermediate High Low Intermediate Low Low
%  DTP3 ofﬁcial coverage [2010]c 92% 72% 94% 95% 97% 96%
Total  population, in thousands [2010]d 17,114 1,224,614 48,184 113,423 142,958 23,162
Birth  cohort, in thousands [2010]d 245 27,165 478 2217 1682 167
<5  mortality rate [2010]d 9 63 5 17 12 6
Economic GAVI eligibilitye No Yes No No No No
World Bank Income Groupf Upper middle Lower middle High Upper middle Upper middle High
GNI  per capita, atlas method, US$ [2010]g $9940 $1340 $19,890 $9330 $9910 $18,573
Health exp as % of total govt exp [2009]a,h 16% 3.7% 12.3% 11.9% 8.50% 6.5
a Health expenditure as a percentage of total government expenditure.
b World Health Organization. WHO  Position Paper on Hepatitis A Vaccines. Weekly Epidemiologic Record. 2012. 87: 261–276. http://www.who.int/wer/
2012/wer8728 29/en/index.html
c World Health Organization. WHO  vaccine-preventable disease monitoring system, 2012 global immunization proﬁle (WHO/UNICEF estimates). Accessed May  1, 2014 at
http://www.who.int/immunization monitoring/data/data subject/en/index.html
d UNICEF. The State of the World’s Children. 2012. Accessed May 1, 2014 at: http://www.unicef.org/sowc/
e GAVI Alliance. GAVI Eligible Countries. 2009. Accessed May  1, 2014 at http://www.gavialliance.org/support/who/eligible/index.php
f World Bank. World Bank Country and Lending Groups. Accessed May  1, 2013 at http://data.worldbank.org/about/country-classiﬁcations/country-and-lending-groups
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accines [1]. Since hepatitis A virus is transmitted through the
ecal-oral route, the incidence of hepatitis A vary according to
evel of socio-economic development. As countries develop and
mprove sanitation and water supply, childhood exposure to the
irus decreases and countries begin an epidemiologic transition,
haracterized by later age at ﬁrst infection and increasing incidence
f symptomatic hepatitis A. The disease may  represent a substan-
ial economic burden in countries transitioning from developing
o developed economies with intermediate and high incidence
ates, where slow recovery and rare serious complications result in
roductivity loss, caregiver burden and medical resource utiliza-
ion. Despite its high efﬁcacy, the hepatitis A vaccine has not been
idely adopted into national immunization programs to date [2,3].
This study simultaneously carried out a literature review on
epatitis A, supplemented by an internet search and policy inter-
iews about the adoption process for hepatitis A vaccine in six
iddle- and high-income countries (Chile, India, South Korea,
exico, Russia, and Taiwan). The literature review focused on cap-
uring epidemiologic, economic or policy articles on hepatitis A in
hese countries, while key informant interviews set out to under-
tand local stakeholder perceptions about the evidence on hepatitis
 infections and its vaccines. The study focused on countries in var-
ous stages of epidemiologic transition and economic development
see Table 1 for key health and economic indicators) to assess if any
aps exist between existing evidence and policies.
. Materials and methods
.1. Literature review
We  conducted a systematic literature search in October 2011
cross ﬁve electronic databases: PubMed®, ISI Web  of Knowl-
dge, EMBASE, Scopus, and EconLit. The search used variations
f two search terms: “hepatitis A” and [one of six countries]. We
ncluded articles primarily focused on hepatitis A epidemiology,
conomics and/or policy. Epidemiologic articles included those
eporting seroprevalence, incidence, prevalence, endemicity, clin-
cal manifestations or risk factors of hepatitis A. Policy articles
ncluded government reports, editorials or reports without primary
ata, which were focused on issues related to vaccine adoption,
revention or control efforts for hepatitis A. We  excluded articles
ess relevant to this analysis, such as papers focusing on biolog-
cal mechanisms of hepatitis A, non-human studies, vaccine trial
esults, and case studies. Given that hepatitis A was  not high onp://data.worldbank.org/indicator
 Database. April, 2011. Last accessed May  1, 2013 at http://www.who.int/nha/
the global agenda prior to 1990, our search was limited to articles
published since then. For most countries, pre-1990 seroprevalence
data was reported in articles published after 1990 providing his-
torical data with trends in seroprevalence over several decades. In
some instances, however, it was necessary to search pre-1990 lit-
erature to ﬁll in data gaps on seroprevalence prior to 1990. Articles
in each of the local languages (Chinese, Korean, Russian, Spanish)
were included in the search. Reference lists of primary studies and
systematic reviews were also scanned to identify additional studies
missed by the initial search. Articles were ﬁrst reviewed for inclu-
sion based on title. Abstracts and full articles were reviewed next
to determine study inclusion.
A supplementary internet search was conducted to ﬁll in gaps
in country-speciﬁc epidemiological data or vaccine policy informa-
tion. Direct scan of ministry of health, pediatric society, infectious
disease society, immunization technical advisory councils, medical
journal databases or other relevant websites was  also conducted
for each country to identify relevant articles or reports, ﬁnd current
recommendations or ﬁll speciﬁc data gaps.
For articles meeting the inclusion criteria, we abstracted data
on background information (authors, title, year of publication and
data collection, journal, country/region, type of article), as well as
study design, study subject characteristics, results, policy recom-
mendations and perceived barriers and facilitators to hepatitis A
vaccine adoption. We  summarized results separately for epidemi-
ologic and policy-focused articles. Articles in Russian, Spanish, and
Chinese were abstracted by native language speakers and writers
of those languages, with a background in healthcare analysis.
2.2. Policy interviews
In-depth interviews were conducted with experts and opin-
ion leaders on hepatitis A in each country, including current and
former government ofﬁcials, authors of articles on hepatitis A,
academics, clinicians, hepatologists, individuals working for inter-
national organizations, vaccine manufacturers, and those in civil
society. Individuals were identiﬁed through the literature search
and personal contacts using snowball sampling. The contact list was
reviewed by country experts to identify the most relevant contacts
and facilitate interviews in some cases. All interviews were carried
out face-to-face by two interviewers, where one individual took
detailed notes. Interviews were held in the capital cities, lasted one
hour, and not digitally recorded. Questions were asked mostly in
English with professional translators used in Taiwan and Russia. In
S. Ozawa et al. / Vaccine 32 (2014) 4089–4096 4091
Fig. 1. Flow chart for study selection.
a Other reasons included: methods-focused article, abstract or conference abstract, or unable to obtain full article.
b s by c
a
C
S
t
s
p
n
a
a
u
q
r
a
ﬁ
l
2
m
t
p
c
sSome articles reported data on multiple countries. We  identiﬁed 352 publication
uthor.
hile and Mexico, some respondents explained some answers in
panish in response to questions in English.
An interview guide was developed and pretested where ques-
ions focused on perceptions of disease burden and the evidence
upporting hepatitis A vaccination, as well as the decision-making
rocesses for adoption of a hepatitis A vaccine into national immu-
ization programs. Interviews also assessed respondent beliefs
bout general policymaker agreement with a series of statements
bout hepatitis A severity and its vaccine.
Detailed interview notes were analyzed by line-by-line coding
sing ATLAS.ti software. A codebook including a priori research
uestions was developed and applied. We  present numbers of
esponses among those who answered speciﬁc questions. Results
re presented in aggregate across respondents to protect the con-
dentiality of individuals. Analyses were conducted at the country
evel and by themes across countries.
.3. Combining the literature review and policy interviews
Data from the literature review, internet search and key infor-
ant interviews were analyzed together to identify gaps betweenhe two sources around epidemiological data, economic data and
olicies around hepatitis A vaccine adoption. For each topic, we
ompared what was said or reported in the literature with what
takeholders reported.ountry. A list of included papers can be obtained by contacting the corresponding
3. Results
The literature and internet search yielded 797 articles. The ini-
tial screening removed 343 articles based on titles and abstracts.
Another 114 articles were excluded upon reading of full-length
articles. This resulted in 340 articles, or 352 by country, as some
articles covered multiple countries (see Fig. 1 for a ﬂow diagram).
The majority of included articles were identiﬁed through PubMed.
India, South Korea and Taiwan (88, 77 and 72 articles) had twice
as many publications as Russia, Chile and Mexico (43, 40 and 32
articles). 312 articles discussed the epidemiology of hepatitis A, 36
articles were on policy and 4 articles on economic analyses. While
all the articles on India were in English, many of the articles in
the other countries were in local languages (Russia 83%, Chile 75%,
Mexico 63%, South Korea 47% and Taiwan 13%).
For policy interviews, a total of 143 individuals were contacted
and 62 interviews were completed in 2012. In Mexico, Russia and
Chile, current and former government employees represented 67%,
50% and 42% of respondents, respectively, compared to 20–30% of
respondents in other countries. Other respondents included clini-
cians (29%), academics (23%), members of civil society (6%), vaccine
manufacturers (2%), and international organization representatives
(2%). Among those not interviewed, 72% did not respond to inter-
view invitations, 15% were unable to participate due to travel, 11%
stated they were not experts on hepatitis A, and 2% could not be
conducted without permission in Russia.
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Table 2
Epidemiologic data on hepatitis A disease.
Chile India South Korea Mexico Russia Taiwan
Literature Endemicity of Hepatitis A,
WHO  Classiﬁcation
Intermediate High Low Intermediate Low Low
Most  Recent Year of
Seroprevalence Data
Santiago: 2001;
Los Lagos: 1999
Western: 2008;
North: 2002;
South: 2002;
Central: 1998;
East: 1998
Seoul: 2010;
Central: 2009;
Northern:
None;
Southern:
2009
Mexico City:
1995; Other:
2006
Moscow/St
Petersburg:
2009; Other:
1999
Northern
(Taipei): 2007;
Central: 2008;
Southern:
2005; Eastern:
2010
Support for the
Epidemiological Transition
Santiago: Late
1970s; Los
Lagos:
Mid-1980s
Western: Yes;
North: No;
South: No;
Central: No;
East: No
Seoul: Late
1980–90s;
Central:
variable data;
Northern:
N/A;
Southern:
variable data
Mexico City:
unclear;
Other: Late
1990s
Data are
variable;
trends unclear
Northern:
Early 1990s;
Central:
variable data;
Southern:
variable data;
Eastern: fully
immunized
No.  of Epidemiology
publications
33 80 75 25 38 65
Most  Recent Year of
Incidence Data
2011 Not identiﬁed Not identiﬁed 2010 2000 2010
Most  Recent Year of
Outbreak Data
2003 2005 2008 None 2002 2007
Perceptions of hepatitis A
disease
Most
decision-makers
would:
Chile India South Korea Mexico Russia Taiwan
Interviews “More infections are now
occurring in young
children and teenagers
than in infants”
Agree 92% 64% 60% 67% 100% 50%
Disagree 0% 18% 30% 17% 0% 40%
Don’t know 8% 18% 10% 8% 0% 10%
“Because seroprevalence
among children is
declining, we  can be less
concerned about Hepatitis
A disease”
Agree 42% 36% 50% 33% 0% 50%
Disagree 50% 64% 40% 58% 80% 40%
Don’t know 8% 0% 10% 8% 20% 10%
“With better water,
sanitation and nutrition
children are not getting
infected early in life,
therefore we don’t need to
be concerned about
Hepatitis A vaccines”
Agree 58% 18% 10% 17% 0% 30%
Disagree 42% 82% 90% 75% 100% 60%
Don’t know 0% 0% 0% 8% 0% 10%
“The  consequences of
Hepatitis A infection
acquired later in life are
very severe and should be a
concern for policy makers”
Agree 58% 80% 80% 100% 40% 100%
Disagree 42% 20% 10% 0% 60% 0%
Don’t know 0% 0% 10% 0% 0% 0%
“Government needs to be
concerned about the severe
illness, and not just deaths,
that can be caused by
Hepatitis A infections”
Agree 92% 89% 70% 100% 100% 90%
Disagree 8% 11% 10% 0% 0% 10%
Don’t know 0% 0% 20% 0% 0% 0%
“How  important a factor is
patients with fulminant
hepatitis A (requiring
transplant or dying) in
decision-making for
adoption of Hepatitis A
Very important 50% 45% 78% 50% 0% 80%
Moderate 25% 18% 0% 17% 40% 20%
Not  important 25% 27% 22% 25% 40% 0%
Don’t know 0% 9% 0% 8% 20% 0%
3
i
hvaccine?”
.1. Epidemiologic data on hepatitis A diseaseEpidemiologic data from the literature were compared with
nterviewees’ general perceptions of data availability and risk of
epatitis A disease (Table 2).There was  strong agreement between the literature and inter-
viewees’ perceptions of the ample epidemiologic evidence on
hepatitis A in South Korea (75 articles) and Taiwan (65 articles).
Many Korean interviewees mentioned epidemiologic data includ-
ing disease burden and infection source of hepatitis A. In Taiwan,
S. Ozawa et al. / Vaccine 32 (2014) 4089–4096 4093
Table  3
Economic data on hepatitis A vaccine.
Key economic data Chile India South Korea Mexico Russia Taiwan
Interviews “How important are
economic studies in
the decision-making
process for a Hepatitis
A vaccine in
[country]?”
Very important 73% 64% 100% 83% 33% 89%
Moderate 18% 36% 0% 17% 33% 11%
Not  imp./Don’t know 9% 0% 0% 8% 34% 0%
“Were  any types of
economic studies for
Hepatitis A done in
[country]?”
Yes 90% 0% 89% 17% 60% 10%
No  0% 64% 0% 42% 20% 80%
Don’t know 10% 36% 11% 42% 20% 10%
“[If  Yes above] Are the
economic studies
sufﬁcient to support an
adoption of a Hepatitis
A  vaccine?”
Yes 67% N/A 71% N/A 25% N/A
No  33% N/A 29% N/A 75% N/A
Literature Type of economic study Cost-
effectiveness
None Economic
analysis
Financial
burden
None None
Main  conclusions Chile Valenzuela, 2005 From the health system perspective, vaccination would cost $460 US per life-year saved, or
$281 US per QALY gained. Savings from healthcare costs would exceed the cost of vaccination
in  7–13 years ($3.9 million US saved within 5- years).
Quezada, 2008 $4,984 per life year gained (base case scenario: 95% vaccine coverage, 100-year time horizon,
1% annual decrease in force of infection); Cost savings were reached after 6 years; Break-even
price for one dose of the vaccine: $48.
South
Korea
Korea CDC, 2010 Most cost beneﬁcial vaccination strategy: vaccinate 90% of 1-year olds and 50% of those 13–18
years; Most effective strategy: vaccinate 50% of those 19–39 years along with 90% of 1-year
olds.
l cost
 case:
(US$7
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eMexico  Rivas-Oropeza, 2009 Annua
minor
pesos 
 number of interviewees expressed conﬁdence in the country’s
urveillance system: “We  have disease burden and reported cases,
ery excellent surveillance.” Published data in South Korea and
aiwan show a downward shift in population seroprevalence over
ime and trends toward infection at older ages [4–7]. A number
f Korean studies showed most people aged 10–29 have no anti-
odies against hepatitis A virus [6,8–11], a trend also mentioned in
aiwan. Recent outbreaks were reported in both countries (2007 in
aiwan, 2008–9 in South Korea) [12–15].In Chile and Russia, the majority of interviewees suggested
hat routine surveillance provided reasonable epidemiological data
n hepatitis A, but recent data were not veriﬁed from the lit-
rature review. Many Chilean respondents were positive about
0% 1
Local vaccine manufacturing capacity
Vaccine safety & effectiveness data
Cost-effectiveness; economic burden data
Availability of combination vaccine
Availaibility of data on Hep A disease
Anti-vaccine movement; distrust of manufacturers
Vaccine procurement, delivery & regulatory challenges
Public awareness; media coverage
Emphasis on sanitation
Global or local recommendations on vaccine
Priority vis-à-vis other vaccines
Political support from government leaders; elections
Disease burden & outbreaks
Budget & price of the vaccine
Both Interviews onlyDiscussed by:
Fig. 2. Barriers and facilitators to h of hepatitis A and its complications: $75.9 million pesos (US$5.9 million); Cost per
 $1,186 pesos (US$92), severe case: $5,942 pesos (US$463), cholestatic case: $9,967
77), fulminant case: $55,798 pesos (US$4,349).
the surveillance data, and our review found sufﬁcient litera-
ture through the 1990s documenting the transition to lower
endemicity [16–22]. The most recent hepatitis A speciﬁc data,
however, were from 2001, with only two  studies [23,24] exam-
ining the changing epidemiology of hepatitis A and the potential
threat it poses. Although the Chile Ministry of Health reports
incidence data from 1975 to 2011, all hepatitis cases are com-
bined, leaving doubts as to the speciﬁc role of hepatitis A: “We
don’t have routine hepatitis A tested. Typing is for B only, and
if not B, then “non-B.” Overall, respondents in Chile reported a
high level of conﬁdence that water and sanitation improvements
had largely addressed disease, except for a small number of
areas.
0% 30% 50% 70% 90%20% 40% 60% 80% 100%
Literature only Neither
epatitis A vaccine adoption.
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In Russia, several respondents reported that disease burden data
s available and cited numbers of cases by region and year; how-
ver, we could not identify such data through the literature review.
he review identiﬁed 38 epidemiological studies in Russia, with
nly two studies reporting seroprevalence data after 2000 [25,26].
ne Russian government respondent noted: “seroprevalence data
or some regions show high antibodies; however, we do not have exact
ata for most regions in different age groups.” Overall, the published
pidemiological data in Russia were quite variable, suggesting vari-
tions in measurement, reporting, or interpretation [27–29]. In
ussia, the literature reported several outbreaks in cities [30] and
ollowing natural disasters [31–33], some of which were mentioned
y respondents.
In India and Mexico, respondents and the literature agreed that
he hepatitis A epidemiological evidence is weak, but some respon-
ents did not ﬁnd this alarming. In India, two respondents said
here were no epidemiologic data available: “[We  have] no mor-
ality, no morbidity, no estimates of economic loss for the poor. But
he technical advisory groups need to have these data to review to
ake decisions.” A few respondents noted recent studies not yet
ompleted and published. The literature review conﬁrmed the
ack of recent seroprevalence data in most areas of India [34–39].
eanwhile, several respondents believed hepatitis A disease is
ot in India and that seroprevalence in India has not changed:
We don’t have [data] and we really don’t need it.” Policy articles
rom 1995 through 2011, however, indicate a growing recogni-
ion of the epidemiological transition in India and the growing
hreat of outbreaks [40–47]: “The epidemiological transition needs
o be documented as well as the potential for outbreak; Kerala was
ne state with a recent outbreak.” A 2005 outbreak in Hyderabad
uggested a change in adult seroprevalence, warranting further
ssessment for vaccination [48]. Currently, there is no national
urveillance system to track outbreaks and the burden of hepatitis
 in India.
In Mexico, respondents noted there is no data by age group,
eography, or socioeconomic status, or data capturing private
mmunizations, disease severity and the extent of fulminant
isease. The overall body of Mexican literature on hepatitis A epi-
emiology was relatively small, with old (1996) seroprevalence
ata for Mexico City [49] and more recent data through 2006 for
ther areas [50–52]. Older data suggest the initiation of the epi-
emiological transition in Mexico [53].
.2. Economic data on hepatitis A vaccine
The majority of stakeholders in 5 out of 6 countries reported that
conomic and ﬁnancial data were very important in the decision
aking process (Table 3). A government implementer in Mexico
oted the Ministry of Health is “quite willing to have a discussion
n hepatitis A; that is why we need cost-effectiveness [data].”  How-
ver, the literature and internet search identiﬁed only 4 economic
nalyses on hepatitis A in the six countries. These included two
ost-effectiveness studies in Chile [54,55] which were referred to
y the interviewees in Chile, one economic analysis model in South
orea [56] also known to Korean respondents, and one study of
he costs of hepatitis A in Mexico [57] which is only published as
n abstract and was not known to the respondents. No economic
nalyses were found in India, Russia or Taiwan.
Even among the published economic studies, data gaps remain.
f the two cost-effectiveness studies in Chile [54,55] respondents
oted the studies are missing the cost of illness for a patient with
epatitis A, and that they were suspicious of economic studies
ponsored by pharmaceutical companies. We  also found that nei-
her models used Chilean cost data, and instead relied on US and
uropean costs of hepatitis A. The 2010 economic model published
y the South Korean Centers for Disease Control did not include (2014) 4089–4096
detailed data on incidence by severity of hepatitis A cases and only
reported per unit costs for different services, leaving gaps in costs
of hepatitis A in South Korea [56].
While economic data are important, respondents cautioned that
it is not the sole decision maker. A vaccine manufacturer in India
noted that economic data are “not the only issue as India looks at
several other impact factors such as infant and maternal mortality.” In
Mexico, a government ofﬁcial noted: “The introduction of the vaccine
could be more costly than the disease itself. For example, pneumococcal
vaccine was controversial at one time because of the cost. One study
showed that it wasn’t cost-effective, but it was still introduced because
of the number of deaths and cases reported.”
3.3. Barriers and facilitators to hepatitis A vaccine adoption
We  identiﬁed 14 barriers and facilitators to adopting the hep-
atitis A vaccine by comparing those discussed in the literature with
those described in interviews by country. Fig. 2 presents these
barriers/facilitators and whether each was  discussed in the liter-
ature and/or interviews.
In general, we found a large gap between barriers and facili-
tators for adoption perceived by stakeholders compared to those
discussed in policy papers. The importance of political sup-
port from government leaders and the role of elections were
brought up as a barrier or facilitator in interviews in every coun-
try (e.g. “this is an election year and it is not good to introduce
anything that costs money.”), but were not mentioned in the
literature. The interviews also discussed the priority for this vaccine
vis-à-vis other vaccines and mentioned global or local recommen-
dations on vaccine adoption, which were rarely discussed in the
literature. A Mexican government ofﬁcial noted, “There are many
other needs for the country and the [Ministry of Health] spends large
sums of money on immunization. It is the money that is the prob-
lem, it is not available.” Other areas less frequently discussed in
the literature but described by stakeholders as barriers were: a
strong emphasis on sanitation, weak public awareness and low
media coverage, challenges in vaccine procurement, delivery and
regulations, anti-vaccine movements and distrust of manufactur-
ers.
On the other hand, barriers more commonly discussed in the
literature were: the lack of data on hepatitis A disease, cost-
effectiveness and other economic data, combination vaccines for
hepatitis A, and the potential for safety and effectiveness data of
the vaccine to facilitate decision making. Immunization budget or
price of the vaccine, and outbreaks of hepatitis A were the only
factors consistently discussed by both sources.
4. Discussion
Our analysis identiﬁed gaps between the published literature
and what key stakeholders believe about epidemiologic data, eco-
nomic data and barriers and facilitators of vaccine adoption for
hepatitis A in six countries. The results of this study highlight sev-
eral areas in which having data from both the literature review and
stakeholder interviews provided additional insights into the fac-
tors driving policy decisions for the hepatitis A vaccine. Regarding
the evidence in support of an epidemiologic transition for hepatitis
A seroprevalence, we found that most often the stakeholders were
aware of the existing data or that very little data existed. How-
ever, in Chile and Russia, stakeholders believed the data to be more
supportive of their positions or more solid than the literature could
document. This discrepancy between the belief in existing data and
what was  found suggest a decline in investment in data collection
or priority of hepatitis A, perhaps due to a reliance on improve-
ments in hygiene and sanitation. The lack of solid data on current
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eroprevalence rates underscores the potential for outbreaks and a
ingering threat of hepatitis A. In India and Mexico, although there
as recognition that data were lacking, there were a surprisingly
mall number of seroprevalence studies despite the size of these
ountries.
Our ﬁndings of limited economic data were consistent between
he literature and the interviews. However, investigation into the
our economic models identiﬁed areas in which current economic
odeling falls short in meeting the needs of policy makers and
n utilizing the best and most relevant data to support country
peciﬁc decision making. Our review suggests the need for addi-
ional investment in economic analyses using country speciﬁc data.
inally, comparison of the barriers and drivers of hepatitis A vaccine
doption noted several differences in factors emphasized by the
iterature and stakeholders. For example, political will and prioriti-
ation of vaccines were barriers rarely mentioned in the literature.
hese data clearly demonstrate that neither source alone would
ave provided the complete picture of relevant factors.
Despite the beneﬁts of using two separate methods for assessing
epatitis A vaccine policy decision making, our results are limited
y the search strategies for the literature review and the sampling
rame for interviews. Our literature search focused primarily on
he published literature supplemented by an internet search of the
ray literature which varied signiﬁcantly in quality. For key infor-
ant interviews, our study resulted in a relatively small sample size
ainly due to the study’s very speciﬁc topic (hepatitis A vaccine
doption) and focus on the viewpoints of government ofﬁcials, sci-
ntists, clinicians and other administrators who  know something
bout the topic. People with program and private sector experience
ere contacted, but many did not respond to interview requests.
espite these limitations, we believe we have identiﬁed and syn-
hesized articles in a systematic manner and provide a glimpse
nto the understandings of key stakeholders of Hepatitis A in each
ountry.
. Conclusions
This study concurrently carried out a systematic literature
eview and key stakeholder interviews to assess gaps between
ocumentation and policy makers’ perceptions in six countries. Tri-
ngulation of results allowed us to identify countries where better
ommunication of existing evidence or greater sharing of existing
on-published evidence would be fruitful. It also highlighted and
onﬁrmed data gaps in seroprevalence or cost-effectiveness stud-
es where both the literature and stakeholders agree that evidence
s missing and would be important to gather. Applying multiple
esearch methods resulted in a more focused attention on the data
aps and evidence-to-policy gaps than if only one method had been
sed. This study also highlights the dearth of seroprevalence data
hat exist in India and Mexico. Further research is needed in these
ountries to highlight the potential health and economic impacts
f hepatitis A disease to help guide vaccination decisions.
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